Study summary
A stem-cell transplant after induction kept more people free of lymphoma than further chemotherapy
78%3-year progression-free with transplant, vs 51%
What was tested
High-dose chemotherapy with autologous stem-cell transplant (thiotepa and carmustine) against two cycles of non-myeloablative R-DeVIC chemotherapy, after four cycles of MATRix induction, in newly diagnosed PCNSL.
What they found
- 3-year progression-free survival was 78% with transplant vs 51% (hazard ratio 0.43).
- Overall survival was also better with transplant.
- Transplant caused more side effects, with five treatment-related deaths vs two.
What it means
Establishes transplant consolidation as the preferred approach for fit patients up to about 70.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.